| 0024-5840 | These highlights do not include all the information needed to use ZALTRAP safely and effectively. See full prescribing information for ZALTRAP. ZALTRAP ® (ziv-aflibercept) injection, for intravenous use Initial U.S. Approval: 2012 | sanofi-aventis U.S. LLC | Regeneron Pharmaceuticals, Inc. | Sanofi-Aventis Deutschland GmbH |
| 0024-5840-01 | These highlights do not include all the information needed to use ZALTRAP safely and effectively. See full prescribing information for ZALTRAP. ZALTRAP ® (ziv-aflibercept) injection, for intravenous use Initial U.S. Approval: 2012 | sanofi-aventis U.S. LLC | Regeneron Pharmaceuticals, Inc. | Sanofi-Aventis Deutschland GmbH |
| 0024-5840-03 | These highlights do not include all the information needed to use ZALTRAP safely and effectively. See full prescribing information for ZALTRAP. ZALTRAP ® (ziv-aflibercept) injection, for intravenous use Initial U.S. Approval: 2012 | sanofi-aventis U.S. LLC | Regeneron Pharmaceuticals, Inc. | Sanofi-Aventis Deutschland GmbH |
| 0024-5841 | These highlights do not include all the information needed to use ZALTRAP safely and effectively. See full prescribing information for ZALTRAP. ZALTRAP ® (ziv-aflibercept) injection, for intravenous use Initial U.S. Approval: 2012 | sanofi-aventis U.S. LLC | Regeneron Pharmaceuticals, Inc. | Sanofi-Aventis Deutschland GmbH |
| 0024-5841-01 | These highlights do not include all the information needed to use ZALTRAP safely and effectively. See full prescribing information for ZALTRAP. ZALTRAP ® (ziv-aflibercept) injection, for intravenous use Initial U.S. Approval: 2012 | sanofi-aventis U.S. LLC | Regeneron Pharmaceuticals, Inc. | Sanofi-Aventis Deutschland GmbH |
| 55513-056 | These highlights do not include all the information needed to use PAVBLU safely and effectively. See full prescribing information for PAVBLU. PAVBLU ® (aflibercept-ayyh) injection, for intravitreal use Initial U.S. Approval: 2024 PAVBLU (aflibercept-ayyh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee | Amgen, Inc | Amgen Singapore Manufacturing Pte. Ltd. |
| 55513-056-01 | These highlights do not include all the information needed to use PAVBLU safely and effectively. See full prescribing information for PAVBLU. PAVBLU ® (aflibercept-ayyh) injection, for intravitreal use Initial U.S. Approval: 2024 PAVBLU (aflibercept-ayyh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee | Amgen, Inc | Amgen Singapore Manufacturing Pte. Ltd. |
| 55513-056-96 | These highlights do not include all the information needed to use PAVBLU safely and effectively. See full prescribing information for PAVBLU. PAVBLU ® (aflibercept-ayyh) injection, for intravitreal use Initial U.S. Approval: 2024 PAVBLU (aflibercept-ayyh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee | Amgen, Inc | Amgen Singapore Manufacturing Pte. Ltd. |
| 55513-065 | These highlights do not include all the information needed to use PAVBLU safely and effectively. See full prescribing information for PAVBLU. PAVBLU ® (aflibercept-ayyh) injection, for intravitreal use Initial U.S. Approval: 2024 PAVBLU (aflibercept-ayyh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee | Amgen, Inc | Amgen Singapore Manufacturing Pte. Ltd. |
| 55513-065-01 | These highlights do not include all the information needed to use PAVBLU safely and effectively. See full prescribing information for PAVBLU. PAVBLU ® (aflibercept-ayyh) injection, for intravitreal use Initial U.S. Approval: 2024 PAVBLU (aflibercept-ayyh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee | Amgen, Inc | Amgen Singapore Manufacturing Pte. Ltd. |
| 55513-065-96 | These highlights do not include all the information needed to use PAVBLU safely and effectively. See full prescribing information for PAVBLU. PAVBLU ® (aflibercept-ayyh) injection, for intravitreal use Initial U.S. Approval: 2024 PAVBLU (aflibercept-ayyh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee | Amgen, Inc | Amgen Singapore Manufacturing Pte. Ltd. |
| 61755-005 | These highlights do not include all the information needed to use EYLEA safely and effectively. See full prescribing information for EYLEA. EYLEA ® (aflibercept) injection, for intravitreal use Initial U.S. Approval: 2011 | Regeneron Pharmaceuticals, Inc. | Vetter Pharma-Fertigung GmbH & Co. KG | Sharp Packaging Services, LLC | Simtra US LLC | Nelson Laboratories | Eurofins Lancaster Laboratories, Inc | Catalent Indiana, LLC | Packaging Coordinators, LLC | Eurofins BioPharma Product Testing Munich GmbH | BioReliance Limited | Regeneron Ireland Designated Activity Company | BioReliance Corporation |
| 61755-005 | These highlights do not include all the information needed to use EYLEA safely and effectively. See full prescribing information for EYLEA. EYLEA ® (aflibercept) injection, for intravitreal use Initial U.S. Approval: 2011 | Regeneron Pharmaceuticals, Inc. | Vetter Pharma Fertigung GmbH & Co. KG (Langenargen Eisenbahnstrasse) | Sharp Packaging Services, LLC | Simtra US LLC | Nelson Laboratories, LLC | Eurofins Lancaster Laboratories, LLC | Catalent Indiana, LLC | Packaging Coordinators, LLC | Eurofins BioPharma Product Testing Munich GmbH | Bioreliance Ltd. | Regeneron Ireland Designated Activity Company | BioReliance Corporation |
| 61755-005-01 | These highlights do not include all the information needed to use EYLEA safely and effectively. See full prescribing information for EYLEA. EYLEA ® (aflibercept) injection, for intravitreal use Initial U.S. Approval: 2011 | Regeneron Pharmaceuticals, Inc. | Vetter Pharma-Fertigung GmbH & Co. KG | Sharp Packaging Services, LLC | Simtra US LLC | Nelson Laboratories | Eurofins Lancaster Laboratories, Inc | Catalent Indiana, LLC | Packaging Coordinators, LLC | Eurofins BioPharma Product Testing Munich GmbH | BioReliance Limited | Regeneron Ireland Designated Activity Company | BioReliance Corporation |
| 61755-005-01 | These highlights do not include all the information needed to use EYLEA safely and effectively. See full prescribing information for EYLEA. EYLEA ® (aflibercept) injection, for intravitreal use Initial U.S. Approval: 2011 | Regeneron Pharmaceuticals, Inc. | Vetter Pharma Fertigung GmbH & Co. KG (Langenargen Eisenbahnstrasse) | Sharp Packaging Services, LLC | Simtra US LLC | Nelson Laboratories, LLC | Eurofins Lancaster Laboratories, LLC | Catalent Indiana, LLC | Packaging Coordinators, LLC | Eurofins BioPharma Product Testing Munich GmbH | Bioreliance Ltd. | Regeneron Ireland Designated Activity Company | BioReliance Corporation |
| 61755-005-02 | These highlights do not include all the information needed to use EYLEA safely and effectively. See full prescribing information for EYLEA. EYLEA ® (aflibercept) injection, for intravitreal use Initial U.S. Approval: 2011 | Regeneron Pharmaceuticals, Inc. | Vetter Pharma-Fertigung GmbH & Co. KG | Sharp Packaging Services, LLC | Simtra US LLC | Nelson Laboratories | Eurofins Lancaster Laboratories, Inc | Catalent Indiana, LLC | Packaging Coordinators, LLC | Eurofins BioPharma Product Testing Munich GmbH | BioReliance Limited | Regeneron Ireland Designated Activity Company | BioReliance Corporation |
| 61755-005-02 | These highlights do not include all the information needed to use EYLEA safely and effectively. See full prescribing information for EYLEA. EYLEA ® (aflibercept) injection, for intravitreal use Initial U.S. Approval: 2011 | Regeneron Pharmaceuticals, Inc. | Vetter Pharma Fertigung GmbH & Co. KG (Langenargen Eisenbahnstrasse) | Sharp Packaging Services, LLC | Simtra US LLC | Nelson Laboratories, LLC | Eurofins Lancaster Laboratories, LLC | Catalent Indiana, LLC | Packaging Coordinators, LLC | Eurofins BioPharma Product Testing Munich GmbH | Bioreliance Ltd. | Regeneron Ireland Designated Activity Company | BioReliance Corporation |
| 61755-005-54 | These highlights do not include all the information needed to use EYLEA safely and effectively. See full prescribing information for EYLEA. EYLEA ® (aflibercept) injection, for intravitreal use Initial U.S. Approval: 2011 | Regeneron Pharmaceuticals, Inc. | Vetter Pharma-Fertigung GmbH & Co. KG | Sharp Packaging Services, LLC | Simtra US LLC | Nelson Laboratories | Eurofins Lancaster Laboratories, Inc | Catalent Indiana, LLC | Packaging Coordinators, LLC | Eurofins BioPharma Product Testing Munich GmbH | BioReliance Limited | Regeneron Ireland Designated Activity Company | BioReliance Corporation |
| 61755-005-54 | These highlights do not include all the information needed to use EYLEA safely and effectively. See full prescribing information for EYLEA. EYLEA ® (aflibercept) injection, for intravitreal use Initial U.S. Approval: 2011 | Regeneron Pharmaceuticals, Inc. | Vetter Pharma Fertigung GmbH & Co. KG (Langenargen Eisenbahnstrasse) | Sharp Packaging Services, LLC | Simtra US LLC | Nelson Laboratories, LLC | Eurofins Lancaster Laboratories, LLC | Catalent Indiana, LLC | Packaging Coordinators, LLC | Eurofins BioPharma Product Testing Munich GmbH | Bioreliance Ltd. | Regeneron Ireland Designated Activity Company | BioReliance Corporation |
| 61755-005-55 | These highlights do not include all the information needed to use EYLEA safely and effectively. See full prescribing information for EYLEA. EYLEA ® (aflibercept) injection, for intravitreal use Initial U.S. Approval: 2011 | Regeneron Pharmaceuticals, Inc. | Vetter Pharma-Fertigung GmbH & Co. KG | Sharp Packaging Services, LLC | Simtra US LLC | Nelson Laboratories | Eurofins Lancaster Laboratories, Inc | Catalent Indiana, LLC | Packaging Coordinators, LLC | Eurofins BioPharma Product Testing Munich GmbH | BioReliance Limited | Regeneron Ireland Designated Activity Company | BioReliance Corporation |
| 61755-005-55 | These highlights do not include all the information needed to use EYLEA safely and effectively. See full prescribing information for EYLEA. EYLEA ® (aflibercept) injection, for intravitreal use Initial U.S. Approval: 2011 | Regeneron Pharmaceuticals, Inc. | Vetter Pharma Fertigung GmbH & Co. KG (Langenargen Eisenbahnstrasse) | Sharp Packaging Services, LLC | Simtra US LLC | Nelson Laboratories, LLC | Eurofins Lancaster Laboratories, LLC | Catalent Indiana, LLC | Packaging Coordinators, LLC | Eurofins BioPharma Product Testing Munich GmbH | Bioreliance Ltd. | Regeneron Ireland Designated Activity Company | BioReliance Corporation |
| 61755-050 | These highlights do not include all the information needed to use EYLEA HD safely and effectively. See full prescribing information for EYLEA HD. EYLEA HD ® (aflibercept) injection, for intravitreal use Initial U.S. Approval: 2011 | Regeneron Pharmaceuticals, Inc |
| 61755-050-00 | These highlights do not include all the information needed to use EYLEA HD safely and effectively. See full prescribing information for EYLEA HD. EYLEA HD ® (aflibercept) injection, for intravitreal use Initial U.S. Approval: 2011 | Regeneron Pharmaceuticals, Inc |
| 61755-050-01 | These highlights do not include all the information needed to use EYLEA HD safely and effectively. See full prescribing information for EYLEA HD. EYLEA HD ® (aflibercept) injection, for intravitreal use Initial U.S. Approval: 2011 | Regeneron Pharmaceuticals, Inc |
| 61755-050-50 | These highlights do not include all the information needed to use EYLEA HD safely and effectively. See full prescribing information for EYLEA HD. EYLEA HD ® (aflibercept) injection, for intravitreal use Initial U.S. Approval: 2011 | Regeneron Pharmaceuticals, Inc |
| 61755-050-51 | These highlights do not include all the information needed to use EYLEA HD safely and effectively. See full prescribing information for EYLEA HD. EYLEA HD ® (aflibercept) injection, for intravitreal use Initial U.S. Approval: 2011 | Regeneron Pharmaceuticals, Inc |
| 61755-051 | These highlights do not include all the information needed to use EYLEA HD safely and effectively. See full prescribing information for EYLEA HD. EYLEA HD ® (aflibercept) injection, for intravitreal use Initial U.S. Approval: 2011 | Regeneron Pharmaceuticals, Inc |
| 61755-051-00 | These highlights do not include all the information needed to use EYLEA HD safely and effectively. See full prescribing information for EYLEA HD. EYLEA HD ® (aflibercept) injection, for intravitreal use Initial U.S. Approval: 2011 | Regeneron Pharmaceuticals, Inc |
| 61755-051-01 | These highlights do not include all the information needed to use EYLEA HD safely and effectively. See full prescribing information for EYLEA HD. EYLEA HD ® (aflibercept) injection, for intravitreal use Initial U.S. Approval: 2011 | Regeneron Pharmaceuticals, Inc |
| 61755-051-50 | These highlights do not include all the information needed to use EYLEA HD safely and effectively. See full prescribing information for EYLEA HD. EYLEA HD ® (aflibercept) injection, for intravitreal use Initial U.S. Approval: 2011 | Regeneron Pharmaceuticals, Inc |
| 61755-051-51 | These highlights do not include all the information needed to use EYLEA HD safely and effectively. See full prescribing information for EYLEA HD. EYLEA HD ® (aflibercept) injection, for intravitreal use Initial U.S. Approval: 2011 | Regeneron Pharmaceuticals, Inc |
| 64406-028 | These highlights do not include all the information needed to use OPUVIZ safely and effectively. See full prescribing information for OPUVIZ. OPUVIZ TM (aflibercept-yszy) injection, for intravitreal use Initial U.S. Approval: 2024 OPUVIZ (aflibercept-yszy) is biosimilar* to EYLEA (aflibercept) | Biogen Inc. | Samsung Bioepis Co., Ltd. |
| 64406-028-01 | These highlights do not include all the information needed to use OPUVIZ safely and effectively. See full prescribing information for OPUVIZ. OPUVIZ TM (aflibercept-yszy) injection, for intravitreal use Initial U.S. Approval: 2024 OPUVIZ (aflibercept-yszy) is biosimilar* to EYLEA (aflibercept) | Biogen Inc. | Samsung Bioepis Co., Ltd. |
| 64406-028-02 | These highlights do not include all the information needed to use OPUVIZ safely and effectively. See full prescribing information for OPUVIZ. OPUVIZ TM (aflibercept-yszy) injection, for intravitreal use Initial U.S. Approval: 2024 OPUVIZ (aflibercept-yszy) is biosimilar* to EYLEA (aflibercept) | Biogen Inc. | Samsung Bioepis Co., Ltd. |
| 64406-028-03 | These highlights do not include all the information needed to use OPUVIZ safely and effectively. See full prescribing information for OPUVIZ. OPUVIZ TM (aflibercept-yszy) injection, for intravitreal use Initial U.S. Approval: 2024 OPUVIZ (aflibercept-yszy) is biosimilar* to EYLEA (aflibercept) | Biogen Inc. | Samsung Bioepis Co., Ltd. |
| 64406-028-04 | These highlights do not include all the information needed to use OPUVIZ safely and effectively. See full prescribing information for OPUVIZ. OPUVIZ TM (aflibercept-yszy) injection, for intravitreal use Initial U.S. Approval: 2024 OPUVIZ (aflibercept-yszy) is biosimilar* to EYLEA (aflibercept) | Biogen Inc. | Samsung Bioepis Co., Ltd. |
| 64406-028-05 | These highlights do not include all the information needed to use OPUVIZ safely and effectively. See full prescribing information for OPUVIZ. OPUVIZ TM (aflibercept-yszy) injection, for intravitreal use Initial U.S. Approval: 2024 OPUVIZ (aflibercept-yszy) is biosimilar* to EYLEA (aflibercept) | Biogen Inc. | Samsung Bioepis Co., Ltd. |
| 64406-028-06 | These highlights do not include all the information needed to use OPUVIZ safely and effectively. See full prescribing information for OPUVIZ. OPUVIZ TM (aflibercept-yszy) injection, for intravitreal use Initial U.S. Approval: 2024 OPUVIZ (aflibercept-yszy) is biosimilar* to EYLEA (aflibercept) | Biogen Inc. | Samsung Bioepis Co., Ltd. |
| 72606-026 | These highlights do not include all the information needed to use EYDENZELT safely and effectively. See full prescribing information for EYDENZELT. EYDENZELT ® (aflibercept-boav) injection, for intravitreal use Initial U.S. Approval: 2025 EYDENZELT ® (aflibercept-boav) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful diff | CELLTRION USA, Inc. | CELLTRION Inc. | BioReliance Ltd | BioReliance Ltd. | WuXi Advanced Therapies, Inc | Samsung Biologics Co., Ltd. | Patheon Italia S.p.A. | STERIPACK MEDICAL POLAND SP Z O O | CELLTRION Pharm, Inc. | Sterigenics Belgium Petit Rechain SA | Sterigenics Germany GmbH |
| 72606-026-01 | These highlights do not include all the information needed to use EYDENZELT safely and effectively. See full prescribing information for EYDENZELT. EYDENZELT ® (aflibercept-boav) injection, for intravitreal use Initial U.S. Approval: 2025 EYDENZELT ® (aflibercept-boav) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful diff | CELLTRION USA, Inc. | CELLTRION Inc. | BioReliance Ltd | BioReliance Ltd. | WuXi Advanced Therapies, Inc | Samsung Biologics Co., Ltd. | Patheon Italia S.p.A. | STERIPACK MEDICAL POLAND SP Z O O | CELLTRION Pharm, Inc. | Sterigenics Belgium Petit Rechain SA | Sterigenics Germany GmbH |
| 72606-026-02 | These highlights do not include all the information needed to use EYDENZELT safely and effectively. See full prescribing information for EYDENZELT. EYDENZELT ® (aflibercept-boav) injection, for intravitreal use Initial U.S. Approval: 2025 EYDENZELT ® (aflibercept-boav) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful diff | CELLTRION USA, Inc. | CELLTRION Inc. | BioReliance Ltd | BioReliance Ltd. | WuXi Advanced Therapies, Inc | Samsung Biologics Co., Ltd. | Patheon Italia S.p.A. | STERIPACK MEDICAL POLAND SP Z O O | CELLTRION Pharm, Inc. | Sterigenics Belgium Petit Rechain SA | Sterigenics Germany GmbH |